Abstract:Objective: To systematically evaluate the efficacy and safety of arbidol in the treatment of novel coronavirus pneumonia (COVID-19). Method(s): Randomized controlled trials (RCTs), cohort studies, and case-control studies on the efficacy and safety of arbidol for COVID-19, influenza, andother respiratory virus infections were collected by searching related database at home and abroad and network platform for preprint of Health Science Papers (medRxiv) (up to April 25, 2020). Quality of the enrolled studies was evaluated by bias risk assessment tool of Cochrane collaboration network and Newcastle-Ottawa Scale (NOS). Meta-analysis and descriptive analysis of relevant outcome indicators were performed using RevMan 5.3 software. Result(s): A total of 15 studies were enrolled in the study, including 7 cohort studies with high-quality and 8 RCTs, 6 of which were with low bias risk and the other 2 of which were with medium bias risk. Among these studies, 8 were on arbidol treatment for COVID-19, including 5 retrospective cohort studies, 2 prospective cohort studies, and 1 RCT, and involving 809 patients (479 patients in the arbidol group and 330 in the control group);7 were RCTs on arbidol treatment for influenza or other respiratory virus infections, involving 1 471 patients (745 patients in the arbidol group and 726 in the control group).In these studies, patients were treated with arbidol (0.15-1.2 g daily for 5-21 d) in the arbidol group while with the other antiviral agents or without any antiviral drug in the control group. Meta analysis on the efficacy and safety of arbidol in treatment for COVID-19 showed that the novel coronavirus (2019-nCoV) nucleic acid negative conversion rate in the arbidol group was significantly higher than that in the control group [71.7% (109/152) vs. 58.8% (94/160), relative risk (RR)=1.30, 95% confidence interval (CI): 1.01-1.67, P=0.04];the difference of time taken for 2019-nCoV nucleic acid negative conversion between the 2 groups was not statistically significant (standardized mean difference=-0.17, 95%CI: -0.72-0.38, P=0.55);the difference of disease improvement rate shown by chest CT on day 7 after treatment between the 2 groups was not statistically significant [46.2% (30/65) vs. 50.7% (36/71), RR=0.88, 95%CI: 0.39-1.98, P=0.76];and the difference of incidence of adverse reactions between the 2 groups was not statistically significant [16.9% (39/231) vs. 19.2% (47/245), risk difference (RD)=-0.03, 95%CI: -0.10-0.04, P=0.44]. Meta analysis on the safety of arbidol in treatment for influenza and other respiratory virus infections showed that the incidence of adverse reactions in the arbidol group was significantly lower than that in the control group [5.9% (44/745) vs. 11.3% (82/726), RR=0.52, 95%CI: 0.37-0.74, P<0.01]. Conclusion(s): Arbidol could effectively increase the 2019-nCoV nucleic acid negative conversion rate and it might be safe to treat COVID-19 using arbidol.Copyright © 2020 by the Chinese Medical Association.

Antiviral Effect of Arbidol Hydrochloride on Adenovirus Type 7 in Vitro

Clinical Efficacy of Arbidol in Patients with 2019 Novel Coronavirus-Infected Pneumonia: A Retrospective Cohort Study

In vitro assessment of the anti-adenoviral activity of artemisinin and its derivatives

Enhancing adenovirus-mediated gene transferin vitro andin vivo by addition of protamine and hydrocortisone

Efficacy and Safety of Arbidol in the Treatment of Novel Coronavirus Pneumonia: a Systematic Review Based on Current and Previous Antiviral Therapy

Antiviral Experiment Research on Extracts from Ardisia Jonica of Different Extract Method in vitro

A randomized controlled clinical trial of arbidol in patients with acute viral upper respiratory infection

Phamacodynamic Study on the Anti-viral Effects in Vitro and in Vivo of Eye Drop Prepared by Mixed Extract of Heartleaf Houttuynia and Lonicera Japonica

Clinical Research on the Treatment of Arbidol Hydrochloride Suspension to Viral Upper Respiratory Tract Infection

Ventilatory responses to inspired CO 2 in patients with cystic fibrosis.

Arbidol: The current demand, strategies, and antiviral mechanisms

Antioxidant Capacity of Flaxseed Products: The Effect of In vitro Digestion

A Bivalent Live-Attenuated Vaccine Candidate Elicits Protective Immunity Against Human Adenovirus Types 4 And 7

Safety of Protease Inhibitors and Arbidol for SARS-CoV-2 Pneumonia in Zhejiang Province, China

[Study on the Effect of Realgar Nanoparticles Anti-Adenovirus in Vitro].

Alterations in bile acids as metabolic signatures in the patients with human adenovirus type 7 infection

Infectivity of human group B adenovirus to cells from different species

Clinical features and efficacy of antiviral drug, Arbidol in 220 nonemergency COVID‐19 patients from East-West-Lake Shelter Hospital in Wuhan: a retrospective case series

A Trial of Arbidol Hydrochloride in Adults with COVID-19

Indirubin-3′-monoxime exhibits potent antiviral and anti-inflammatory effects against human adenoviruses in vitro and in vivo

Early antiviral therapy of abidor combined with lopinavir/ritonavir and re combinant interferonα 2b in patients with novel coronavirus pneumonia in Zhejiang: A multicenter and prospective study